CN102762560A - 二取代的杂芳基-稠合的吡啶 - Google Patents

二取代的杂芳基-稠合的吡啶 Download PDF

Info

Publication number
CN102762560A
CN102762560A CN2010800643114A CN201080064311A CN102762560A CN 102762560 A CN102762560 A CN 102762560A CN 2010800643114 A CN2010800643114 A CN 2010800643114A CN 201080064311 A CN201080064311 A CN 201080064311A CN 102762560 A CN102762560 A CN 102762560A
Authority
CN
China
Prior art keywords
pyrazolo
ring system
pyridin
acetamide
yloxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800643114A
Other languages
English (en)
Chinese (zh)
Inventor
S·巴迪格
D·本克
C·贝特斯查尔特
V·乔杜里
M·舍布罗鲁
S·科斯特斯塔
S·安特曼
C·潘迪特
A·迈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102762560A publication Critical patent/CN102762560A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800643114A 2009-12-21 2010-12-20 二取代的杂芳基-稠合的吡啶 Pending CN102762560A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2664DE2009 2009-12-21
IN2664/DEL/2009 2009-12-21
PCT/EP2010/070260 WO2011076744A1 (en) 2009-12-21 2010-12-20 Disubstituted heteroaryl-fused pyridines

Publications (1)

Publication Number Publication Date
CN102762560A true CN102762560A (zh) 2012-10-31

Family

ID=43640661

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800643114A Pending CN102762560A (zh) 2009-12-21 2010-12-20 二取代的杂芳基-稠合的吡啶

Country Status (6)

Country Link
US (1) US8742106B2 (enExample)
EP (1) EP2516437B1 (enExample)
JP (1) JP2013515032A (enExample)
CN (1) CN102762560A (enExample)
ES (1) ES2460915T3 (enExample)
WO (1) WO2011076744A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105541719A (zh) * 2016-02-03 2016-05-04 安徽工业大学 一种以乳清酸为原料制备5-氨基-1,2二氢吡唑-3-酮的方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2672732T3 (es) 2012-02-07 2018-06-15 Eolas Therapeutics Inc. Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
BR102012024778A2 (pt) 2012-09-28 2014-08-19 Cristalia Prod Quimicos Farm Compostos heteroaromáticos; processo para preparar os compostos, composições farmacêuticas, usos e método de tratamento para as dores aguda e crônica
UY36272A (es) 2014-08-13 2016-02-29 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores de los receptores de orexinas
EP3954685B1 (en) 2014-12-29 2025-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
TWI710557B (zh) 2016-02-12 2020-11-21 美商伊歐拉斯治療學公司 作為食慾素受體調節劑之經鹵素取代之六氫吡啶
US20190281828A1 (en) 2016-09-22 2019-09-19 Bayer Cropscience Aktiengesellschaft Novel triazole derivatives
EP3515907A1 (en) 2016-09-22 2019-07-31 Bayer CropScience Aktiengesellschaft Novel triazole derivatives
MX2019003714A (es) 2016-09-29 2019-06-24 Bayer Cropscience Ag Novedosos derivados de imidazolilmetilo 5-sustituidos.
BR112019006441A2 (pt) 2016-09-29 2019-06-25 Bayer Ag derivados de 5-imidazol metil dioxolano substituídos como fungicidas
WO2018145932A1 (en) 2017-02-08 2018-08-16 Bayer Cropscience Aktiengesellschaft Triazole derivatives and their use as fungicides
WO2018145933A1 (en) 2017-02-08 2018-08-16 Bayer Aktiengesellschaft Triazolethione derivatives
EP3580218A1 (en) 2017-02-08 2019-12-18 Bayer CropScience Aktiengesellschaft Novel triazole derivatives
US20200008426A1 (en) 2017-02-10 2020-01-09 Bayer Aktiengesellschaft Active compound combinations
WO2020020816A1 (en) 2018-07-26 2020-01-30 Bayer Aktiengesellschaft Novel triazole derivatives
EP3867224A1 (en) * 2018-10-18 2021-08-25 Boehringer Ingelheim International GmbH Scalable synthesis of optically active 1-cyclopropylalkyl-1-amines
KR20230104193A (ko) * 2020-11-02 2023-07-07 머크 샤프 앤드 돔 엘엘씨 마크로시클릭 우레아 오렉신 수용체 효능제

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098301A1 (en) * 2000-06-20 2001-12-27 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
WO2007122591A2 (en) * 2006-04-26 2007-11-01 Actelion Pharmaceuticals Ltd Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
WO2009003993A1 (en) * 2007-07-03 2009-01-08 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2232038A1 (de) 1972-06-30 1974-01-10 Hoechst Ag 3-amino-1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine, ihre herstellung und verwendung
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US6670364B2 (en) 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
US6962926B2 (en) 2001-01-31 2005-11-08 Telik, Inc. Antagonist of MCP-1 function, and compositions and methods of use thereof
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7601876B2 (en) * 2002-05-31 2009-10-13 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
DE102004061288A1 (de) 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
EP1764099A3 (en) 2005-09-17 2007-05-09 Speedel Experimenta AG Diaminoalcohol derivatives for the treatment of Alzheimer, malaria, HIV
JP2007099640A (ja) 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
TW200815438A (en) 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1870410A1 (en) 2006-06-13 2007-12-26 Bayer Schering Pharma Aktiengesellschaft Substituted arylpyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
GB0617161D0 (en) 2006-08-31 2006-10-11 Vernalis R&D Ltd Enzyme inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001098301A1 (en) * 2000-06-20 2001-12-27 Japan Tobacco Inc. Pyrazolopyridine compounds and use thereof as drugs
WO2007122591A2 (en) * 2006-04-26 2007-11-01 Actelion Pharmaceuticals Ltd Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
WO2009003993A1 (en) * 2007-07-03 2009-01-08 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JIAQIANG CAI ET AL: "Antagonists of the orexin receptors", 《EXPERT OPIN.THER.PATENTS》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105541719A (zh) * 2016-02-03 2016-05-04 安徽工业大学 一种以乳清酸为原料制备5-氨基-1,2二氢吡唑-3-酮的方法

Also Published As

Publication number Publication date
EP2516437B1 (en) 2014-01-29
EP2516437A1 (en) 2012-10-31
JP2013515032A (ja) 2013-05-02
US20120258973A1 (en) 2012-10-11
US8742106B2 (en) 2014-06-03
WO2011076744A1 (en) 2011-06-30
ES2460915T3 (es) 2014-05-16

Similar Documents

Publication Publication Date Title
CN102762560A (zh) 二取代的杂芳基-稠合的吡啶
JP6355648B2 (ja) Ｗｎｔシグナル伝達経路の３−（ベンゾイミダゾール−２−イル）−インダゾール阻害剤およびそれらの治療的使用
JP7023243B2 (ja) イソキノリン－３イル－カルボキサミドならびにその調製および使用の方法
RU2682245C1 (ru) Индазольные ингибиторы сигнального пути wnt и их терапевтические применения
CN102365277B (zh) Jun n-末端激酶抑制剂
JP6181862B2 (ja) ピラゾロピロリジン誘導体および疾患の処置におけるその使用
JP6373978B2 (ja) イミダゾピロリジノン誘導体および疾患の処置におけるその使用
US8163756B2 (en) Enzyme modulators and treatments
CN102105451B (zh) 葡糖激酶活化剂
TWI873185B (zh) 唑稠合之嗒-3(2h)-酮衍生物
US8242143B2 (en) Thiazolyl mGluR5 antagonists and methods for their use
WO2019101178A1 (zh) 作为c-MET/AXL抑制剂的尿嘧啶类化合物
KR20190014505A (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
BRPI0915084B1 (pt) Composto, e, composição farmacêutica
KR20150120383A (ko) 신규 피라졸 유도체
CN102762567A (zh) 作为食欲肽受体拮抗剂的二氮杂-螺[5.5]十一烷类
US20120165331A1 (en) Di/tri-aza-spiro-C9-C11alkanes
WO2002064211A1 (en) Thrombin inhibitors
EP1812112B1 (en) Benzodiazepine derivatives as ROCK kinases inhibitors
CN106414443A (zh) 吡啶并嘧啶二酮衍生物
JP6564394B2 (ja) 複素環式化合物およびそのドーパミンｄ１リガンドとしての使用
JP2008510734A (ja) キナーゼ阻害剤
WO2022089219A1 (zh) 芳基酰胺化合物、包含其的药物组合物及其制备方法和用途
WO2022028556A1 (zh) Cdk9抑制剂及其用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis AG

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS AG TO: NOVARTIS CO., LTD.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20121031